Based on the information received, clinical evaluation confirmed the reported type iiia endoleak with complete aortic component separation, type iiib endoleak of the cuff and rupture.Clinical evaluation was unable to confirm that the patient is to receive no treatment due to deteriorating condition.Additionally, clinical evaluation found a complete crown separation, and hyperdilation of the cuff (76%).The most likely cause of the mid aortic loss of seal was the stretched fabric of the cuff (76%) in combination with aortic remodeling.The most likely cause of the compromised stent graft integrity (stretched and breached) was the use of strata material.The most likely cause of the proximal loss of seal was the complete crown separation that was related to the use of strata material.It was reported the patient would receive no further treatment and was in deteriorating condition.There have been no reports of further negative patient sequelae.The devices remain implanted in the patient and will not be returned; therefore, device evaluation will not be completed.The review of manufacturing lot confirmed all devices met specifications prior to release.The afx bifurcated stent was previously reported to the fda under mfr# 2031527-2018-00175.
|